Circassia competitors

Circassia Competitors include Durect, Amarin, Array BioPharma and Clinigen Group.
Add company...
Circassia
Circassia
Circassia is a specialty biopharmaceutical company focused on developing novel immunotherapies
Durect
Durect
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.
Amarin
Amarin
Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease.
Array BioPharma
Array BioPharma
Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
Clinigen Group
Clinigen Group
A specialty pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time
Founding Date
Founding Date
2006
Founding Date
N/A
Founding Date
1991
Founding Date
1998
Founding Date
2010
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Oxford, GB HQ
Solna, SE
Chicago, US
Locations
Cupertino, US HQ
Locations
Dublin, IE HQ
Bedminster Township, US
Locations
Boulder, US HQ
Miami, US
Boston, US
Phoenix, US
New York, US
Chicago, US
Houston, US
see more
Locations
Burton upon Trent, GB HQ
Employees
Employees
400
Employees
903% decrease
Employees
241
Employees
209
Employees
465200% increase
Valuation ($)
Valuation ($)
339 m
Valuation ($)
120.7 m
Valuation ($)
6.7 b
Valuation ($)
5.2 b
Valuation ($)
1.8 b

Financial

Revenue (est.)
Revenue (est.)
£17k (FY, 2016)
Revenue (est.)
$18.6m (FY, 2018)
Revenue (est.)
$229.2m (FY, 2018)
Revenue (est.)
$173.8m (FY, 2018)
Revenue (est.)
£339.6m (FY, 2018)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$54.5m (FY, 2018)
Cost of goods
N/A
Cost of goods
£216.1m (FY, 2018)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
$174.7m (FY, 2018)
Gross profit
N/A
Gross profit
£123.6m (FY, 2018)
Net income
Net income
£17k (FY, 2016)
Net income
($25.3m) (FY, 2018)
Net income
($116.4m) (FY, 2018)
Net income
($147.3m) (FY, 2018)
Net income
£24.4m (FY, 2018)

Funding

Total funding raised
Total funding raised
$ 122.8m
Total funding raised
$ 20m
Total funding raised
$ 70m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Durect
HQ
Cupertino, US
Employees
90↓ 3% decrease

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.

View company
Amarin
HQ
Dublin, IE
Employees
241

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease.

View company
Array BioPharma
HQ
Boulder, US
Employees
209

Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

View company
Clinigen Group
HQ
Burton upon Trent, GB
Employees
465

A specialty pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time

View company